Novel Therapies for NSCLC With EGFR Exon 20 Insertions: Practical Pearls for the Clinic

Are you aware that there are now targeted therapies available for patients harboring exon 20 insertions, the third most common type of EGFR mutation in non-small cell lung cancer (NSCLC)? Credit available for this activity expires: 6/20/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975726?src=mkm_podcast_addon_975726